1st September 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

USFDA issues observations to Biocon Biologics

Following an inspection of seven manufacturing facilities owned by its subsidiary Biocon Biologics, the US health regulator issued Form 483s with 11 observations for each of two sites in Bengaluru and six observations for a plant in Malaysia

Delhi HC rejects Sun Pharma's appeal against Hetero for violating its trade mark Letro

Sun Pharmaceutical Laboratories filed an appeal against Hetero Healthcare alleging that its trade mark Letroz for second-line treatment of advanced breast cancer had been violated. The appeal was dismissed by a division bench of the Delhi High Court.

35% of pharmaceutical industry's output emerges from Himachal

Speaking at the Himachal Drug Manufacturers Association, Union Minister of State said, “The state accounted for 35% of the country’s pharmaceutical production, with Baddi alone producing 20%. “

Orchid Pharma to invest up to Rs 500 crore to establish a unit under the PLI scheme

Under the production-linked incentive (PLI) scheme, Orchid Pharma will invest Rs 300- 500 crore over the following two years to establish a new plant to produce essential key starting materials or drug intermediaries.

Himachal Pradesh's CM thanks Prime Minister Narendra Modi for allocating Bulk Drug Pharma Park to state

Jai Ram Thakur, the chief minister, expressed gratitude to Prime Minister Narendra Modi and the federal government for granting the State access to the Bulk Drug Pharma Park.

Zydus receives FDA approval for Venlafaxine and Pregabalin tablets

USFDA has granted final approval to Zydus Lifesciences Limited to market two medications: Pregabalin extended-release tablets, USP 82.5 mg, 165 mg, and 330 mg; and Venlafaxine extended-release tablets, USP 37.5 mg, 75 mg, 150 mg, and 225 mg.

Sanofi & Sobi's BLA for efanesoctocog alfa to treat haemophilia A given priority review by USFDA

Biologics License Application for efanesoctocog alfa (BIVV001), a rare and potentially fatal bleeding disorder, has been accepted for priority review by the US Food and Drug Administration (FDA). 

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Welcome to PharmaState Academy

Install
×
Start chat
1
Need Help?
PharmaState Academy
Hello, how can we help you?